FDA DRUG REGULATION - GREG CONKO
Medicalprogresstoday.com:FDA's Qnexa Decision and the Value of Benefit/Risk Analysis
In a surprise move, the Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee on Wednesday voted 20 to 2 in favor of recommending approval of the obesity drug Qnexa. If the agency accepts that recommendation and ultimately approves Qnexa, it would become the first new obesity treatment in over a decade. Just a year and a half ago, however, the same committee (though with a slightly different composition) voted 10 to 6 against approving the same drug. What changed their minds? > Find out at Medical Progress Today
CEI is a non-profit, non-partisan public policy group dedicated to the principles of free enterprise and limited government. For more information about CEI, please visit our website, cei.org, and blogs, Globalwarming.org and OpenMarket.org. Follow CEI on Twitter! Twitter.com/ceidotorg.